Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (4)

Page 1 sur 1

Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?

Alessandra Griffa

The preclinical phase of Alzheimer’s disease represents a crucial time window for therapeutic intervention but requires the identification of clinically relevant biomarkers that are sensitive to the effects of disease-modifying drugs. Amyloid peptide and t ...

Oxford University Press2025

Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer's Disease

Loïc Dayon

Although neuropsychiatric symptoms (NPS) are common and severely affect older people with cognitive decline, little is known about their underlying molecular mechanisms and relationships with Alzheimer's disease (AD). The aim of this study was to identify ...

MDPI2022

Longitudinal expression changes are weak correlates of disease progression in Huntington's disease

Irina Krier

Huntington's disease is a severe but slowly progressive hereditary illness for which only symptomatic treatments are presently available. Clinical measures of disease progression are somewhat subjective and may require years to detect significant change. T ...

OXFORD UNIV PRESS2020

"Switch peptides" : conception et synthèse d'inhibiteurs ou destructeurs potentiels de fibrilles amyloïdes

Lydiane Jeanine Saucède

Despite of considerable progress in the research at the interface of Chemistry, Biology and Medicine, neurodegenerative diseases affect more and more seriously our ageing population and remain a real therapeutic challenge for researcher. Nevertheless, adva ...

EPFL2006